Hirsutism

TREATMENT OF PCOS Treatment of PCOS is complex and is individualised. It depends on the symptoms with which the patient presents and her age. The treatment falls broadly in 3 categories: treating menstrual dysfunction, androgen-related symptoms and infertility1. Treatment of menstrual irregularity is with low-dose combined contraceptive pills or with cyclic progestin to induce a withdrawal bleeding, the former however is recommended. Lifestyle modifications should nevertheless be promoted. Treatment

Cushing’s syndrome (CS) is an endocrine disorder that leads to a lot of symptoms in the human body. A chronic excess of cortisol in the bloodstream characterizes CS. Besides the traditional pathways of treatment (which include surgery, radiotherapy and use of medicines), a new advance in the pharmacological treatment of CS is being tested: Agent LCI699. Recent data ratify that the efficacy and safety of the LCI699 are promising in the reduction of the levels of cortisol. When incorporated to an

low grade inflammation, however despite the risk factors clustering, studies have not been able to correlate a uniform association between PCOS and cardiovascular disease (Pasquali et al., 2011). Oxidative stress can also be present in non-obese PCOS patients. Cardiovascular disease is increased by PCOS, therapies for this particular symptom could include the use of antioxidants as a corrective measure, to improve the effects of oxidative stress by reducing insulin resistance and hyperandrogenism

Polycystic ovarian syndrome is among the long list of chronic diseases one could suffer from. “A chronic disease is a disease that persists for a long time, lasting longer than 3 months and generally cannot be prevented by vaccines or cured by medication, nor do they disappear” (MedicineNet, 2017) Per the National Center for Health Statistics, “88% of Americans over 65 years of age have at least one chronic health condition”. (MedicineNet, 2017) There are numerous contributors to chronic diseases

Anabolic-androgenic steroids (AAS) are synthetic compounds have two action androgenic and anabolic these effect depend on chemical structure of testosterone , AAS used for treatment indifferent conditions such as delay puberty , reproductive system dysfunction, breast cancer and anemia (2). AAS clinically has been replaced by erythropoietin due to sever side effect . athletes used for increase performance , lean muscle mass, muscular strength and Increases aggressiveness and confidence

Facial Hairs Several factors can influence your probabilities of developing facial hairs. These factors include: • Family history- Several reasons that cause unwanted facial hairs are hereditary. These conditions, including congenital adrenal hyperplasia and polycystic ovary syndrome. • Ethnicity: Women of Mediterranean, Middle Eastern and South Asian strains are more likely to develop unwanted facial hair with no identifiable cause than women of other ethnicities. What are the causes of unwanted

Even if the percentage for hormonal and gonadal abnormalities is more compared to chromosomal abnormalities in SA, cytogenetic investigation is a must. The percentage of total CA (16%) in SA of the present study will hold good with previous studies which vary from 5 – 33.3% and pure numerical abnormalities (45,X; 47,XXX) could not be observed (table 3). The CA observed was only X mosaicism in two of the studies (gupta, Butnarui) as compared to present study (16/43%). The percentage for X mosaicism

have been made to minimize this toxicity, such as monitoring drug blood levels, modifying the protocol, and co-administering other agents. Other side effects caused by CsA “are hepatotoxicity, hyperkalemia, hypertension, tremor, gum overgrowth, and hirsutism.” (NCBI) Another dose-related immunosuppressive agent is Azathioprine (AZA). This causes dose-related bone marrow suppression, commonly leading to leukopenia. Therefore, a careful monitoring of complete blood cell count and dosage adjustment according

The treatment of Cushing’s syndrome can be achieved from different drugs found in different classes. The classes in which these drugs are found is namely; Steroidogenic inhibitors which consists of drugs such as Metyrapone, Ketoconazole, Etomidate, and Aminoglutethimide; Adrenolytic agents which consists of Milotane; Neuromodulators of adrenocorticotropic hormone (ACTH) which consists of Cyproheptadine and Pasireotide; and lastly, Glucocorticoid receptor blocking agents which consist of Mifepristone

(Nguyen, 2015) states the following: In 1912, Cushing syndrome was described first by Harvey. The signs and symptoms associated with this disease arecaused by excess glucocorticoids that float around freely in the plasma. The excess glucocorticoids could be as a result of increased endogenous production or prolonged exposure to exogenous use of glucocorticoid products. While endogenous Cushing’s syndrome is a rare disease which is either drug-related or exogenousin nature.Cushing syndrome from